302
Views
3
CrossRef citations to date
0
Altmetric
Original Research

Bicalutamide causes heart failure in an elderly patient with prostate cancer

Pages 297-302 | Received 23 Aug 2015, Accepted 10 Dec 2015, Published online: 08 Jan 2016

References

  • Furr BJA, Tucker H. The preclinical development of bicalutamide: pharmacodynamics and mechanism of action. Urology. 1996;47:13–35.
  • Georget V, Térouanne B, Nicolas J-C, et al. Mechanism of antiandrogen action: key role of Hsp90 in conformational change and transcriptional activity of the androgen receptor. Biochemistry. 2002;41:11824–11831. DOI:10.1021/bi0259150.
  • Floyd MSJ, Teahan SJ, Fitzpatrick JM, et al. Differential mechanisms of bicalutamide-induced apoptosis in prostate cell linesBicalutamide-induced apoptosis in prostate cell lines. Prostate Cancer Prostatic Dis. 2008;12:25–33.
  • Morrissey C, Brown M, O’Sullivan J, et al. Epigallocatechin-3-gallate and bicalutamide cause growth arrest and apoptosis in NRP-152 and NRP-154 prostate epithelial cells. Int J of Urol. 2007;14:545–551. DOI:10.1111/j.1442-2042.2007.01774.x.
  • Product Information: Casodex(R), bicalutamide (2000d) Zeneca Pharmaceuticals, Wilmington, DE.
  • Cockshott ID, Cooper KJ, Sweetmore DS, et al. The pharmacokinetics of Casodex in prostate cancer patients after single and during multiple dosing. Eur Urol. 1990;18:10–17.
  • Kolvenbag GJCM, Blackledge GRP, Gotting-Smith K. Bicalutamide (Casodex®) in the treatment of prostate cancer: history of clinical development. Prostate. 1998;34:61–72.
  • Writing Group. Micromedex: Thomson Healthcare [ cited 2015 Mar 13].
  • Iversen P. The third analysis of the bicalutamide Early Prostate Cancer programme. BJU Int. 2006;97:438–439.
  • Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239–245.
  • Sternberg CN. Apples and oranges. BJU Int. 2006;97:435–443.
  • Albertsen PC, Klotz L, Tombal B, et al. Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist. Eur Urol. 2014;65:565–573.
  • Dockery F, Bulpitt CJ, Agarwal S, et al. Anti-androgens increase N-terminal pro-BNP levels in men with prostate cancer. Clin Endocrin. 2008;68:59–65. DOI:10.1111/j.1365-2265.2007.02999.x.
  • Ikeda Y, Aihara K, Yoshida S, et al. Androgen-androgen receptor system protects against angiotensin II-induced vascular remodeling. Endocrin. 2009;150:2857–2864. DOI:10.1210/en.2008-1254.
  • Nakamura M. Peripheral vascular remodeling in chronic heart failure: clinical relevance and new conceptualization of its mechanisms. J Card Fail. 1999;5(2):127–138.
  • Poelzl G, Frick M, Huegel H, et al. Chronic heart failure is associated with vascular remodeling of the brachial artery. Eur J Heart Fail. 2005;7(1):43–48. DOI:10.1016/j.ejheart.2004.04.008.
  • Ikeda Y, Aihara K, Sato T, et al. Androgen Receptor Gene Knockout Male Mice Exhibit Impaired Cardiac Growth and Exacerbation of Angiotensin II-induced Cardiac Fibrosis. J Biol Chem. 2005;280:29661–29666.
  • Mäkinen J, Järvisalo MJ, Pöllänen P, et al. Increased Carotid Atherosclerosis in Andropausal Middle-Aged Men. J Am Coll Cardiol. 2005;45(10):1603–1608.
  • Muller M, van den Beld AW, Bots ML, et al. Endogenous sex hormones and progression of carotid atherosclerosis in elderly men. Circulation. 2004;109:2074–2079.
  • Polak JF, Meisner A, Pencina MJ, et al. Incident congestive heart failure and common carotid artery diameter: the Framingham offspring study. Circulation. 2011;124:A13709.
  • Gottdiener JS, Arnold AM, Aurigemma GP, et al. Predictors of congestive heart failure in the elderly: the cardiovascular health study. J Am Coll Cardiol. 2000;35(6):1628–1637.
  • Trachtenberg J. Emerging pharmacologic therapies for prostate cancer. Rev in Urol. 2001;3(3):S23–S28.
  • D’Antonio JM. Analysis of endothelin during androgen deprivation: implications for prostate cancer progression [ Doctoral Dissertation]. Pittsburgh (PA): University of Pittsburgh; 2007.
  • Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nature Rev: Cancer. 2001;1:34–45.
  • Balk SP. Androgen receptor as a target in androgen-independent prostate cancer. Urology. 2002;60(3 Suppl 1):132–138.
  • Dai Z, Aoki T, Fukumoto Y, et al. Coronary perivascular fibrosis is associated with impairment of coronary blood flow in patients with non-ischemic heart failure. J Cardiol. 2012;60(5):416–421.
  • Jasmin J, Lucas M, Cernacek P, et al. Effectiveness of a Nonselective ETA/B and a Selective ETA Antagonist in Rats With Monocrotaline-Induced Pulmonary Hypertension. Circulation. 2001;103:314–318.
  • Ajayi AA, Fidelis P. The effect of flutamide on systemic and renal hemodynamics in Zucker diabetic rats: paradoxic renal vasodilator response to endothelin-1 and TXA2 receptor activation in female sex. J Cardiovasc Pharmacol. 2006;48(5):191–198.
  • Pflug B, McHugh K, D’Antonio J, et al. Defining the basis of an operational model for enhanced efficacy of combination therapy using an endothelin receptor antagonist and chemotherapeutic agents. Mol Cancer Ther. 2007;6:A287.
  • Lüscher TF, Barton M. Endothelins and Endothelin Receptor Antagonists Therapeutic Considerations for a Novel Class of Cardiovascular Drugs. Circulation. 2000;102:2434–2440.
  • Gustafsson AB, Gottlieb RA. Bcl-2 family members and apoptosis, taken to heart. Am J Physiol - Cell Physiol. 2007;292(1):C45–C51.
  • Limana F, Urbanek K, Chimenti S, et al. bcl-2 overexpression promotes myocyte proliferation. PNAS. 2002;99(9):6257–6262.
  • Katayama H, Murashima T, Saeki Y, et al. The pure anti-androgen bicalutamide inhibits cyclin A expression both in androgen-dependent and -independent cell lines. Int J Oncol. 2010;36:553–562.
  • Woo YJ, Panlilio CM, Cheng RK, et al. Therapeutic Delivery of Cyclin A2 Induces Myocardial Regeneration and Enhances Cardiac Function in Ischemic Heart Failure. Circulation. 2006;114(1 Suppl):I206–13.
  • Shapiro SD, Ranjan AK, Kawase Y, et al. Cyclin A2 induces cardiac regeneration after myocardial infarction through cytokinesis of adult cardiomyocytes. Sci Transl Medication. 2014;6(224):224–227.
  • Cheng RK, Asai T, Tang H, et al. 2007. Cyclin A2 induces cardiac regeneration after myocardial infarction and prevents heart failure. Circulation Res. 100:1741–1748. DOI:10.1161/CIRCRESAHA.107.153544.
  • Heeneman S, Sluimer JC, Daemen MJAP. Angiotensin-Converting Enzyme and Vascular Remodeling. Circulation Res. 2007;101:441–454.
  • Irani K. Angiotensin II–stimulated vascular remodeling: the search for the culprit oxidase. Circulation Res. 2001;88:858–860.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.